JP2019501881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501881A5 JP2019501881A5 JP2018528300A JP2018528300A JP2019501881A5 JP 2019501881 A5 JP2019501881 A5 JP 2019501881A5 JP 2018528300 A JP2018528300 A JP 2018528300A JP 2018528300 A JP2018528300 A JP 2018528300A JP 2019501881 A5 JP2019501881 A5 JP 2019501881A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- melflufen
- administered
- dosage
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 23
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 208000034578 Multiple myelomas Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 238000001802 infusion Methods 0.000 claims description 10
- 239000003186 pharmaceutical solution Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229960004942 lenalidomide Drugs 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229960002204 daratumumab Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229960000688 pomalidomide Drugs 0.000 claims description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- YQZNKYXGZSVEHI-VXKWHMMOSA-N ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 YQZNKYXGZSVEHI-VXKWHMMOSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- ZCMWSKHHXLCVHI-VROPFNGYSA-N ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 ZCMWSKHHXLCVHI-VROPFNGYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229950009924 melphalan flufenamide Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 229940124622 immune-modulator drug Drugs 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 229940045681 other alkylating agent in atc Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521217.8 | 2015-12-01 | ||
| GBGB1521217.8A GB201521217D0 (en) | 2015-12-01 | 2015-12-01 | Dosage regimens |
| PCT/EP2016/079511 WO2017093443A1 (en) | 2015-12-01 | 2016-12-01 | Melflufen dosage regimens for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021010894A Division JP2021088560A (ja) | 2015-12-01 | 2021-01-27 | がんに対するメルフルフェン投薬計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501881A JP2019501881A (ja) | 2019-01-24 |
| JP2019501881A5 true JP2019501881A5 (enExample) | 2020-11-12 |
| JP6878431B2 JP6878431B2 (ja) | 2021-05-26 |
Family
ID=55177548
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528300A Active JP6878431B2 (ja) | 2015-12-01 | 2016-12-01 | がんに対するメルフルフェン投薬計画 |
| JP2021010894A Pending JP2021088560A (ja) | 2015-12-01 | 2021-01-27 | がんに対するメルフルフェン投薬計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021010894A Pending JP2021088560A (ja) | 2015-12-01 | 2021-01-27 | がんに対するメルフルフェン投薬計画 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20180369141A1 (enExample) |
| EP (3) | EP3383385B2 (enExample) |
| JP (2) | JP6878431B2 (enExample) |
| KR (2) | KR20210092327A (enExample) |
| CN (1) | CN108289876A (enExample) |
| AU (2) | AU2016363591B2 (enExample) |
| BR (1) | BR112018010012A8 (enExample) |
| CA (1) | CA3003102C (enExample) |
| CY (1) | CY1123469T1 (enExample) |
| DK (1) | DK3383385T4 (enExample) |
| ES (1) | ES2828033T5 (enExample) |
| FI (1) | FI3383385T4 (enExample) |
| GB (1) | GB201521217D0 (enExample) |
| HR (1) | HRP20201632T4 (enExample) |
| HU (1) | HUE051525T2 (enExample) |
| IL (2) | IL301019B2 (enExample) |
| LT (1) | LT3383385T (enExample) |
| MX (2) | MX384724B (enExample) |
| PL (1) | PL3383385T5 (enExample) |
| PT (1) | PT3383385T (enExample) |
| RS (1) | RS60986B2 (enExample) |
| RU (2) | RU2020134307A (enExample) |
| SG (1) | SG11201803551YA (enExample) |
| SI (1) | SI3383385T2 (enExample) |
| SM (1) | SMT202000567T1 (enExample) |
| WO (1) | WO2017093443A1 (enExample) |
| ZA (2) | ZA201802816B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3116198A1 (en) * | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
| EP4588484A3 (en) * | 2019-01-28 | 2025-10-15 | Sanofi-Aventis U.S. LLC | Methods of treating multiple myeloma |
| WO2020201542A1 (en) * | 2019-04-03 | 2020-10-08 | Oncopeptides Ab | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) * | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| SE544998C2 (en) * | 2021-01-13 | 2023-02-21 | Bkmdcl Ab | Peptide conjugates of melphalan for the treatment of cancer |
| US20240307480A1 (en) * | 2021-07-08 | 2024-09-19 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) * | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| SMT202000447T1 (it) * | 2011-04-28 | 2020-09-10 | Oncopeptides Ab | Preparazione liofilizzata di dipeptidi citotossici |
| WO2014065741A1 (en) | 2012-10-22 | 2014-05-01 | Parker Hannifin Manufacturing Sweden Ab | Joystick |
| BR112015009280B1 (pt) * | 2012-10-26 | 2022-05-31 | Oncopeptides Ab | Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes |
| SG11201508272YA (en) * | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
-
2015
- 2015-12-01 GB GBGB1521217.8A patent/GB201521217D0/en not_active Ceased
-
2016
- 2016-12-01 SG SG11201803551YA patent/SG11201803551YA/en unknown
- 2016-12-01 SI SI201630963T patent/SI3383385T2/sl unknown
- 2016-12-01 CN CN201680070133.3A patent/CN108289876A/zh active Pending
- 2016-12-01 LT LTEP16805792.5T patent/LT3383385T/lt unknown
- 2016-12-01 EP EP16805792.5A patent/EP3383385B2/en active Active
- 2016-12-01 HR HRP20201632TT patent/HRP20201632T4/hr unknown
- 2016-12-01 PT PT168057925T patent/PT3383385T/pt unknown
- 2016-12-01 JP JP2018528300A patent/JP6878431B2/ja active Active
- 2016-12-01 SM SM20200567T patent/SMT202000567T1/it unknown
- 2016-12-01 RU RU2020134307A patent/RU2020134307A/ru unknown
- 2016-12-01 EP EP21179365.8A patent/EP3903777A1/en active Pending
- 2016-12-01 KR KR1020217022171A patent/KR20210092327A/ko not_active Withdrawn
- 2016-12-01 WO PCT/EP2016/079511 patent/WO2017093443A1/en not_active Ceased
- 2016-12-01 MX MX2018006706A patent/MX384724B/es unknown
- 2016-12-01 RS RS20201289A patent/RS60986B2/sr unknown
- 2016-12-01 BR BR112018010012A patent/BR112018010012A8/pt not_active Application Discontinuation
- 2016-12-01 US US15/779,609 patent/US20180369141A1/en not_active Abandoned
- 2016-12-01 RU RU2018123718A patent/RU2734930C2/ru active
- 2016-12-01 CA CA3003102A patent/CA3003102C/en active Active
- 2016-12-01 AU AU2016363591A patent/AU2016363591B2/en active Active
- 2016-12-01 KR KR1020187014234A patent/KR102279629B1/ko active Active
- 2016-12-01 EP EP20187064.9A patent/EP3750534A1/en not_active Withdrawn
- 2016-12-01 FI FIEP16805792.5T patent/FI3383385T4/fi active
- 2016-12-01 ES ES16805792T patent/ES2828033T5/es active Active
- 2016-12-01 PL PL16805792.5T patent/PL3383385T5/pl unknown
- 2016-12-01 DK DK16805792.5T patent/DK3383385T4/da active
- 2016-12-01 IL IL301019A patent/IL301019B2/en unknown
- 2016-12-01 HU HUE16805792A patent/HUE051525T2/hu unknown
-
2018
- 2018-04-26 ZA ZA2018/02816A patent/ZA201802816B/en unknown
- 2018-05-02 IL IL259101A patent/IL259101A/en unknown
- 2018-05-31 MX MX2021008738A patent/MX2021008738A/es unknown
-
2020
- 2020-10-21 CY CY20201100994T patent/CY1123469T1/el unknown
-
2021
- 2021-01-22 AU AU2021200436A patent/AU2021200436A1/en not_active Abandoned
- 2021-01-27 JP JP2021010894A patent/JP2021088560A/ja active Pending
- 2021-03-24 US US17/210,699 patent/US20220047507A1/en not_active Abandoned
- 2021-04-14 ZA ZA2021/02438A patent/ZA202102438B/en unknown
-
2024
- 2024-11-08 US US18/942,039 patent/US20250144023A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501881A5 (enExample) | ||
| CA2856646C (en) | Combination treatment of cancer | |
| JP2022068180A5 (enExample) | ||
| EP3524268A1 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| JP2019507797A5 (enExample) | ||
| JP4708569B2 (ja) | 血管形成を伴う疾患の治療に対する併用 | |
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| Dunne et al. | A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270) | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JP2014502608A5 (enExample) | ||
| JP2019178177A5 (enExample) | ||
| KR20050054921A (ko) | 저알부민 상태의 개선제 | |
| JP2016510738A5 (enExample) | ||
| CN102327599A (zh) | 用于治疗骨髓增生异常综合征的组合物和方法 | |
| CN110891574B (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| WO2012144619A1 (ja) | 経口投与用慢性肝疾患治療剤 | |
| JPH11171763A (ja) | 肝疾患治療剤 | |
| CA3106783A1 (en) | Combination therapy for treating cancer | |
| JP2019001830A (ja) | 医薬 | |
| CN107519171A (zh) | 洛匹那韦减轻伊立替康毒性的医药新用途 | |
| Yamamoto et al. | Multicenter Analysis of mFOLFOX6 with Oxaliplatin Stop-and-Go Strategy Using Oral Uracil-Tegafur with Leucovorin for Unresectable Colorectal Cancer in Elderly Patients | |
| TH2201000080A (th) | การรวมกันของไอบูโพรเฟนและทรามาดอลสำหรับการบรรเทาอาการปวด | |
| MX2021003288A (es) | Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica. | |
| CN107281462A (zh) | 沙奎拉韦减轻伊立替康毒性的医药新用途 | |
| Reynolds et al. | Patient satisfaction with fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain |